Amplicon expression vector vaccines
AssigneesLineaRx, Inc., EvviVax S.r.l.
InventorsMichael E. Hogan, Stephen Hughes, Antonella Conforti, Luigi Aurisicchio, Fabio Palombo
Life of this patent
Estimating the term…
Abstract
Provided herein are non-plasmid derived DNA vaccines comprised solely of enzymatically produced amplicon expression vectors and their method of use to elicit antigen-specific immune responses in a subject. The enzymatically produced amplicon expression vectors may be specifically utilized as a DNA based cancer vaccine to express desired antigens or other immunogenic polypeptides within a subject to induce a specific anti-cancer antigen-specific immune response. The enzymatically produced amplicon expression vectors may also be utilized to express cancer-specific neoantigens.
Claims20
A method of treating cancer in a subject, said method comprising:
- Identifying in a subject cancer neoantigens;
- Without the use of plasmid-derived DNA, assembling an amplicon expression vector template comprising a promotor, one or more open reading frames (ORF) encoding the identified neoantigens and a terminator via gene synthesis;
- amplifying the amplicon expression vector template via the polymerase chain reaction (PCR) and phosphorothioate modified PCR primers to produce a plurality of amplicon expression vectors;
- purifying and concentrating the amplicon expression vectors to create an efficacious therapeutic dose for the subject;
- and
- administering the therapeutic dose of amplicon expression vectors via electroporation in conjunction with one or more immune checkpoint inhibitors.
A method of prophylactically treating cancer in a subject, said method comprising:
- Without the use of plasmid-derived DNA, assembling an amplicon expression vector template comprising a promotor, an ORF encoding a consensus sequence for telomerase reverse transcriptase and terminator;
- amplifying the amplicon expression vector template via the polymerase chain reaction (PCR) and phosphorothioate modified PCR primers to produce a plurality of amplicon expression vectors;
- purifying and concentrating the amplicon expression vectors to create an efficacious prophylactic dose for the subject;
- and
- administering the prophylactic dose of amplicon expression vectors via electroporation.
A method of treating cancer in a subject, said method comprising:
- Without the use of plasmid-derived DNA, assembling an amplicon expression vector template comprising a promotor, an ORF encoding a consensus sequence for telomerase reverse transcriptase and terminator;
- amplifying the amplicon expression vector template via the polymerase chain reaction (PCR) and phosphorothioate modified PCR primers to produce a plurality of amplicon expression vectors;
- purifying and concentrating the amplicon expression vectors to create an efficacious therapeutic dose for the subject;
- and
- administering the therapeutic dose of amplicon expression vectors via electroporation in conjunction with one or more immune checkpoint inhibitors.
Dependencies are inferred from the claim text.